More on ISIS

- Summary
- Chart
- Profile
- Historical


- Earnings
- Ratings
- Holders


Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (8/4/15 *Est.)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

ISIS Income Statement

Click line-items for a historical chart and %
Research and development revenue under collaborative agreements 43.8M
Licensing and royalty revenue 265K
Total revenue 44.06M
Research and development
General and administrative 4.47M
Total operating expenses 65.56M
Loss from operations -21.49M
Other income (expense):
Equity in net loss of Regulus Therapeutics Inc.
Investment income 675K
Interest expense -5M
Gain (loss) on investments, net 538K
Loss before income tax expense
Income tax expense
Net loss
Basic net loss (in dollars per share)
Diluted net loss (in dollars per share)
Shares used in computing basic net loss per share (in shares)
Shares used in computing diluted net loss per share (in shares)